Chief Medical Officer- Executive Vicepresident
Ayala Pharmaceuticals
Dr. Gutierrez has served as Ayala (formerly Advaxis) Executive Vice President and Chief Medical Officer since April 2018. Prior to joining Ayala, Dr. Gutierrez served as Chief Medical Officer for Oncolytics Biotech, Inc. from November 2016 to April 2018. Prior to Oncolytics, Dr. Gutierrez was Chief Medical Officer at SELLAS Life Sciences Group from November 2015 to September 2016 and was Medical Director, Early Development Immuno-Oncology at BMS from October 2012 to November 2015, where he oversaw the development of translational and clinical development of immuno-oncology programs in solid tumors and hematological malignancies, including leading early development of relatlimab. Earlier, Dr. Gutierrez was Medical Director for several biotechnology companies, including Sunesis Pharmaceuticals, BioMarin Pharmaceutical, Proteolix and Oculus Innovative Sciences, leading key programs with talazoparib and carfilzomib, among others. Prior to Oculus, he served as Director of the Gene & Cell Therapy Unit at the National Institutes of Health in Mexico City and as a consultant physician at the Hospital Angeles del Pedregal. Dr. Gutierrez holds MD and PhD degrees with specialization in Internal Medicine from UNAM-IMSS Mexico and a fellowship in oncology at the Hammersmith Hospital, London UK.
